Go Pro

Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Up 796.7% in August

Fresenius SE & Co. logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Short interest surged 796.7% to 1,029,832 shares as of August 14, up from 114,842 shares on July 30. The stock’s days-to-cover ratio is 2.5, although reported short interest remains 0.0% of shares outstanding.
  • Analysts remain positive, with Morgan Stanley maintaining an “overweight” rating and Deutsche Bank reaffirming a “buy” rating. All three tracked analysts rate Fresenius SE & Co. a Buy.
  • Shares recently fell 0.6% to $13.39. In its latest quarter, Fresenius reported $0.24 in EPS—slightly below estimates—but revenue of $6.91 billion exceeded the $6.65 billion consensus forecast.
  • Five stocks to consider instead of Fresenius SE & Co..

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 1,029,832 shares, an increase of 796.7% from the July 30th total of 114,842 shares. Based on an average daily volume of 420,053 shares, the days-to-cover ratio is presently 2.5 days. Currently, 0.0% of the company's shares are sold short.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on FSNUY. Morgan Stanley reissued an "overweight" rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy".

Read Our Latest Research Report on FSNUY

Fresenius SE & Co. Stock Down 0.6%

Shares of OTCMKTS FSNUY traded down $0.08 during midday trading on Tuesday, reaching $13.39. 58,204 shares of the company's stock were exchanged, compared to its average volume of 155,321. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $33.93. The business's fifty day moving average price is $12.53 and its two-hundred day moving average price is $12.70. The stock has a market capitalization of $30.17 billion, a PE ratio of 16.95 and a beta of 0.61.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.33% and a net margin of 6.67%. Analysts forecast that Fresenius SE & Co. will post 1.08 EPS for the current year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Fresenius SE & Co. Right Now?

Before you consider Fresenius SE & Co., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. wasn't on the list.

While Fresenius SE & Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines